Sam Andi Dhedie Prasatia, Warsinggih Warsinggih, Usman Muhammad Andry, Johan Muhammad Phetrus, Suroto Heri, Saleh M Ruksal, Sakti Muhammad, Zainuddin Andi Alfian, Mubarak Andi Firman
Faculty of Medicine, Universitas Muslim Indonesia, Makassar, Indonesia.
Doctoral Study Program, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia.
Stem Cells Cloning. 2025 Apr 9;18:35-43. doi: 10.2147/SCCAA.S512079. eCollection 2025.
Chronic tendon injuries often lead to diminished healing capacity, necessitating innovative treatments. Mesenchymal stem cells (MSCs) secretome has emerged as a promising option for enhancing tendon repair through paracrine signaling. This study evaluates the effectiveness of MSC secretome, derived from tendon-derived stem cells (TDSCs) and adipose-derived stem cells (ASCs) in healing chronic Achilles tendon injuries in a rat model. The focus is on Procollagen Type I N-Terminal Peptide (PINP) and Procollagen Type III N-Terminal Peptide (PIIINP) levels, and histopathological changes.
Fourteen adult male rats were divided into four groups: Group I (TDSC secretome), Group II (ASC secretome), Group III (combination of TDSC and ASC secretome), and Group IV (control). The healing response was assessed through PINP and PIIINP immunoserological markers, and histopathological changes were analyzed. The study adhered to ARRIVE and ICLAS guidelines and followed the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals.
The combination group showed significantly higher PINP levels compared to the control group (p = 0.004), suggesting enhanced Type I collagen synthesis. However, no significant differences in PIIINP levels were observed among the groups. Histopathological analysis showed no significant differences in collagen alignment or angiogenesis between treatment and control groups.
The MSC secretome, particularly the combination of TDSCs and ASCs, may accelerate collagen Type I synthesis and improve tendon microstructure. This suggests their potential for treating chronic tendon injuries. However, further research with longer observation periods and clinical trials is crucial to confirm these findings and advance our understanding of tendon healing.
慢性肌腱损伤常导致愈合能力下降，需要创新的治疗方法。间充质干细胞（MSC）分泌组已成为通过旁分泌信号增强肌腱修复的一个有前景的选择。本研究评估了源自肌腱来源干细胞（TDSC）和脂肪来源干细胞（ASC）的MSC分泌组在大鼠模型中治疗慢性跟腱损伤的有效性。重点关注I型前胶原N端肽（PINP）和III型前胶原N端肽（PIIINP）水平以及组织病理学变化。
将14只成年雄性大鼠分为四组：第一组（TDSC分泌组）、第二组（ASC分泌组）、第三组（TDSC和ASC分泌组联合）和第四组（对照组）。通过PINP和PIIINP免疫血清学标志物评估愈合反应，并分析组织病理学变化。本研究遵循ARRIVE和ICLAS指南，并遵循美国国立卫生研究院（NIH）实验动物护理和使用指南。
联合组的PINP水平显著高于对照组（p = 0.004），表明I型胶原合成增强。然而，各组之间PIIINP水平未观察到显著差异。组织病理学分析显示，治疗组和对照组之间在胶原排列或血管生成方面无显著差异。
MSC分泌组，特别是TDSC和ASC的联合，可能加速I型胶原合成并改善肌腱微观结构。这表明它们在治疗慢性肌腱损伤方面具有潜力。然而，进行更长观察期的进一步研究和临床试验对于证实这些发现并推进我们对肌腱愈合的理解至关重要。
